Trusted Resource for Clinical Trials, Protocols & Progress
In clinical trials, data discrepancies between laboratory systems and site-collected data are a persistent challenge. These mismatches—ranging from missing values to differing units or delayed transfers—can raise significant compliance risks. The FDA, EMA, and ICH E6(R2) emphasize the need for formalized SOPs to address and reconcile such inconsistencies.
Click to read the full article.
The reconciliation of data between laboratory systems and site-collected records is a critical aspect of data integrity in clinical trials. Discrepancies, if unmanaged, can compromise subject safety, trial outcomes, and regulatory compliance. Regulatory authorities such as the FDA and EMA expect robust CAPA (Corrective and Preventive Action) procedures to be implemented when such discrepancies occur.
Click to read the full article.
In clinical trials, reconciliation between laboratory data and electronic data capture (EDC) systems ensures integrity, consistency, and regulatory compliance. Delays in this process can lead to data discrepancies, patient safety risks, and regulatory inspection findings.
Click to read the full article.
In clinical trials, reconciliation between laboratory results and electronic data capture (EDC) systems is critical for ensuring data integrity and regulatory compliance. When this reconciliation is delayed or incomplete, it can result in protocol deviations that impact patient safety and data quality. Regulatory authorities, including the FDA and EMA, view such deviations as serious non-compliances if not addressed appropriately.
Click to read the full article.
Role-Based Access Control (RBAC) is critical to safeguarding laboratory and EDC data in clinical trials. As reconciliation involves data entry, validation, and resolution of discrepancies across systems, only authorized users must access specific data elements. Without proper RBAC, unauthorized access could lead to untraceable changes, audit trail gaps, or data integrity violations — all of which are flagged during inspections by regulatory authorities such as the FDA or EMA.
Click to read the full article.
Data reconciliation between Laboratory Information Management Systems (LIMS) and Electronic Data Capture (EDC) platforms is a cornerstone of clinical trial quality assurance. Discrepancies may arise due to sample labeling mismatches, data entry errors, timing variances, or incorrect transfer protocols. While single-instance deviations may be managed, recurring discrepancies or trending errors indicate systemic issues that demand deeper investigation through a CAPA (Corrective and Preventive Action) framework.
Click to read the full article.
In multi-site clinical trials, laboratory results and clinical data are often managed across diverse geographies, time zones, vendors, and systems. This fragmented landscape increases the likelihood of discrepancies between lab results, source documents, and EDC entries. Without a centralized reconciliation log, resolving these discrepancies becomes cumbersome, error-prone, and non-compliant with regulatory expectations.
Click to read the full article.
In recent years, global regulatory bodies like the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and MHRA have intensified their scrutiny of data reconciliation practices in clinical trials. The reconciliation process—ensuring that laboratory data matches with entries in the Electronic Data Capture (EDC) system—is critical to upholding data integrity. Discrepancies between the lab and clinical data records not only risk misleading results but also violate Good Clinical Practice (GCP) guidelines.
Click to read the full article.
Clinical trial success hinges on reliable data. One critical area often overlooked is the reconciliation of laboratory data with the Electronic Data Capture (EDC) system. Regulatory bodies such as the FDA, EMA, and PMDA have repeatedly identified data reconciliation failures as significant Good Clinical Practice (GCP) non-compliance during inspections.
Click to read the full article.
Data reconciliation between laboratory systems and electronic data capture (EDC) platforms is a critical step in ensuring data integrity in clinical trials. In multi-country trials, the complexity of managing disparate systems, languages, and regulations makes reconciliation even more challenging. As such, the establishment of robust, inspection-ready Standard Operating Procedures (SOPs) for reconciliation cycles is essential to avoid regulatory scrutiny and ensure accurate trial reporting.
Click to read the full article.
